| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | DROSHA; RN3; RNASE3L; RNASEN; Ribonuclease 3; Protein Drosha; Ribonuclease III; RNase III; p241 |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human RNase III Drosha. AA range:774-823 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets DROSHA and detects endogenous levels of DROSHA protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | DROSHA |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~159.3 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human RNase III Drosha. AA range:774-823 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 29102; Mouse: 14000 |
| UniProt | Q9NRR4 (Human: Q9NRR4; Mouse: Q5HZJ0) |
Scientific Background
Members of the ribonuclease III superfamily of double-stranded (ds) RNA-specific endoribonucleases participate in diverse RNA maturation and decay pathways in eukaryotic and prokaryotic cells (Fortin et al. 2002 [PubMed 12191433]). The RNase III Drosha is the core nuclease that executes the initiation step of microRNA (miRNA) processing in the nucleus (Lee et al. 2003 [PubMed 14508493]).
Alternative Names
DROSHA; RN3; RNASE3L; RNASEN; Ribonuclease 3; Protein Drosha; Ribonuclease III; RNase III; p241
Safety & Handling
| Target | DROSHA |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~159.3 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human RNase III Drosha. AA range:774-823 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 29102; Mouse: 14000 |
| UniProt | Q9NRR4 (Human: Q9NRR4; Mouse: Q5HZJ0) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Members of the ribonuclease III superfamily of double-stranded (ds) RNA-specific endoribonucleases participate in diverse RNA maturation and decay pathways in eukaryotic and prokaryotic cells (Fortin et al. 2002 [PubMed 12191433]). The RNase III Drosha is the core nuclease that executes the initiation step of microRNA (miRNA) processing in the nucleus (Lee et al. 2003 [PubMed 14508493]).
Alternative Names
DROSHA; RN3; RNASE3L; RNASEN; Ribonuclease 3; Protein Drosha; Ribonuclease III; RNase III; p241
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
